Figure 1From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)Kaplan-Meier curves for the study end points. (A) Progression-free survival (PFS), (B) Overall survival (OS).Back to article page